Company Overview and News


Add 532321
to your dashboard

Headline News

Zydus’ oral small molecule named Desidustat by WHO

2017-11-20 thehindubusinessline
Drug firm Zydus Cadila today said its oral anaemia developmental candidate, ZYAN1, has been named Desidustat by the World Health Organisation (WHO) INN Committee. (2-0)

Zydus#39; oral small molecule named Desidustat by WHO

2017-11-20 moneycontrol
Drug firm Zydus Cadila today said its oral anaemia developmental candidate, ZYAN1, has been named Desidustat by the World Health Organisation (WHO) INN Committee. (2-0)

Cadila Healthcare Limited - Press Release

2017-11-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (17-0)

Weekly wrap: Pharma stocks end Nov 13-17 week in red as Q2 results fail to spur investor interest

2017-11-18 moneycontrol
The November 13-17 week was a lacklustre one for pharma stocks. US approval of Cipla’s anti-asthma drug and Eris Lifesciences acquisition of Strides Shasun's India branded business were the highlights of the week. Sun Pharmaceutical Industries and Cadila Healthcare second quarter results were the major result announcements this week. (4-0)

Cadila Healthcare Limited - Press Release

2017-11-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (17-0)

Cadila Healthcare Limited - Investor Presentation

2017-11-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (17-0)

Cadila Healthcare Q2 profit up 32% at Rs503 crore

2017-11-14 livemint
New Delhi: Drug firm Cadila Healthcare on Tuesday reported a 32.48% rise in its consolidated net profit to Rs503.3 crore for the second quarter ended 30 September, mainly on account of robust sales in the US and India. (2-0)

Cadila Healthcare's Q2 net up 33% to Rs 503 cr

2017-11-14 business-standard
As a premium subscriber you get an across device unfettered access to a range of services which include: (2-0)

Cadila Healthcare net profit jumps 33% in Q2 on strong US India formulation sales

2017-11-14 moneycontrol
Drug maker Cadila Healthcare on Tuesday reported 33 percent rise in net profit to Rs 503 crore in the second quarter ended September benefited by strong US formulation sales led by 180-day exclusivity of generic anti-ulcer drug Lialda. (2-0)

Cadila Healthcare Limited - Press Release

2017-11-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (17-0)

Cadila Healthcare Limited - Financial Result Updates

2017-11-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (17-0)

What changed for the market while you were sleeping? 20 things you should know

2017-11-14 moneycontrol
The Nifty started on a muted note on Monday and failed to pull the index back above 10,300 which it was able to do in the past two sessions. The Nifty opened at 10,322 and rose marginally to hit an intraday high of 10,334. It slipped to an intraday low of 10,216 before closing the day at 10,224, down 96 points. (23-0)

NBCC, Sun Pharma to announce results today

2017-11-13 thehindubusinessline
Over 200 companies will declare their July-September quarter results on Tuesday. Among these are 3M India, Advanced Enzyme, Bank of Baroda, BASF, Bata India, Bhushan Steel, Cadila Healthcare, Ceat, Corporation Bank, Cox & Kings, Dilip Buildcon, DB Realty, Eicher Motors, GAIL, Godrej Ind, Grasim, HDIL, IFCI, Indiabulls Real, IPCA Labs, ITDC, JP Associates, Lanco Infra, MOIL, NBCC, NCC, Reliance Capital, Sun Pharma, Tata Global and Unitech. (6-0)

Zydus gets Mexico approval for diabetes drugs

2017-11-12 thehindubusinessline
Cadila Healthcare has said in a statement that the Mexican regulatory authority COFEPRIS has granted marketing approval to commercialise Lipaglyn (Saroglitazar magnesium) in Mexico. The drug is used to treat dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins. Zydus is also evaluating Saroglitazar to treat liver conditions. (2-0)

Cadila Healthcare gets Mexican regulatory nod to market Lipaglyn drug

2017-11-10 thehindubusinessline
Drug firm Cadila Healthcare on Friday said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes. The company has been granted marketing approval by the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to commercialise Lipaglyn in Mexico, Zydus said in a statement. (2-0)